Notch signaling can regulate a wide variety of cellular processes, including apoptosis 1 differentiation, 2 and drug resistance. 3 At the molecular level, Notch signaling has been demonstrated to function as a transcriptional activator. 4 Receptor-ligand interaction renders Notch susceptible to cleavage by ADAM-type metalloproteases at site S2, which creates a short-lived intermediate, which is in turn cleaved by g-secretase within the transmembrane domain at site S3. This frees the intracellular domain of Notch (Notch-IC), which translocates to the nucleus to form a transcriptional activation complex with the DNA-binding factor CSL. That the Notch signaling pathway has a crucial role in cancer is firmly established as a rare T-cell acute lymphoblastic leukemia (T-ALL)-associated genetic lesion has been initially reported to result in deletion of Notch1 ectodomain and constitutive activation of its intracellular region. 5 Further studies have shown that activating mutations in the NOTCH1 gene are present in over 50% of human T-ALL cases, making NOTCH1 the most prominent oncogene specifically involved in the pathogenesis of this disease. [5] [6] [7] In T-ALL, activation of Notch signaling has been implicated in the regulation of multiple cellular pathways, including those resulting in apoptosis, 8 tissue infiltration 9 and glucocorticoid resistance. 10 The link between Notch and glucocorticoid resistance is of particular interest, as glucocorticoids were among the first drug classes used in the treatment of patients with T-cell leukemia and are still the essential components of treatment (Inaba and Pui in 11 and references therein). They seem to exert their cytotoxic effects Accepted article preview online 13 July 2012; advance online publication, 31 July 2012 by binding to glucocorticoid receptors in the cytoplasm. These receptors can then form dimers, translocate to the nucleus and interact with glucocorticoid-response elements to transactivate gene expression, or they can remain as monomers and repress the activity of transcription factors, such as the activating protein-1 or nuclear factor-kB. [12] [13] [14] Published results suggest that inhibition of Notch1 signaling enhances glucocorticoid receptor auto-upregulation and glucocorticoid sensitivity in otherwise glucocorticoid-resistant T-ALL cells. 10 Short-hairpin RNA knockdown of HES-1 in T-ALLderived cells resulted in increased glucocorticoid receptor transcript and protein levels and effective reversal of glucocorticoid resistance. 15 In order to study the relationship between Notch1/ Hes-1 expression and glucocorticoid sensitivity, we determined the relative expression of Notch1/Hes-1 by quantitative PCR and western blot analysis in both glucocorticoid-sensitive and -resistant T cells. Thus, we compared Notch1 and Hes-1 levels in dexamethasone (DEX)-resistant cell lines (Jurkat and Molt3) and the glucocorticoid-sensitive cell line (KE-37). We found that, in contrast with the presence of Notch1, Hes-1 expression was downmodulated in KE-37 cells ( Figure 1 ). Interestingly, Jurkat and Molt3 cells are highly resistant to glucocorticoids, showing only a minimal loss of cell viability when treated with DEX concentrations as high as 1 mM (Figure 1e ). Conversely, treatment of KE-37 cells with 100 nM DEX for 48 h effectively induces an apoptotic response, as revealed by cell viability assay and poly (ADP-ribose) polymerase (PARP) cleavage (Figures 1e and f) . It has been reported that inhibition of Notch1 target, Hes-1, can reverse glucocorticoid resistance in leukemic lymphoblasts by inducing upregulation of NR3C1 (nuclear receptor subfamily 3, group C, member 1, also known as GR or GCR); 15 in agreement with this model, we found a correspondence between Hes-1 expression and GC resistance. We found that Hes-1 is expressed in both Jurkat and Molt3, and, as expected, 15 we found that the level of NR3C1 protein is low in both these cell lines (Figure 1h , only Jurkat cells are shown). Conversely, we found that KE-37 cells did not express Hes-1 but expressed a higher level of NR3C1 when compared with both Jurkat and Molt3 cells (Figure 1h ). To elucidate the mechanism responsible for the GC-induced apoptosis in KE-37 cells treated with glucocorticoids, we performed a western blot analysis against Notch1 of the T leukemic cells treated with vehicle or DEX. This analysis identified Notch1 as a gene that is regulated by DEX (Figure 1g) . Interestingly, dose-response analysis of KE-37 cells treated with DEX (100 nM and 1 mM) showed that DEX is effective in promoting Notch1 down-modulation. Conversely, analysis of Jurkat and Molt3 cells treated with DEX (100 nM and 1 mM) showed that Notch1 expression was unaffected by GC treatment. To understand at which level Notch1 expression was regulated by GC treatment, we first characterized the NOTCH1 promoter region by using the Genomatix MatInspector software package (Genomatix, Munchen, Germany; www.genomatix.de). A scan of 2.5 kb of genomic sequence, located upstream of the predicted pre-NOTCH1 start site, identified several putative glucocorticoid responsive elements (GRE) in both the human and the mouse NOTCH1 regulatory region (Figure 2a) , suggesting the involvement of a direct binding of GC to the NOTCH1 promoter. Thus, we examined the role of GC in the control of NOTCH1 expression by generating a NOTCH1 promoter construct and testing it in a luciferase reporter assay. We found that the level of NOTCH1 promoter activity was strongly reduced by GC treatment in a dose-dependent manner with both human and mouse promoter (Figure 2b , only the human promoter is shown). To ascertain whether NR3C1 occupies the NOTCH1 promoter in vivo, we performed a chromatin immunoprecipitation assay using formaldehyde cross-linked KE-37 cells. Chromatin extracts were subjected to immunoprecipitation with anti-NR3C1 antibodies. These samples were subjected to PCR amplification with the use of specific oligos that target the GRE region of the NOTCH1 promoter. As shown in Figure 2c , anti-NR3C1 antibodies recovered a 300 bp fragment of the NOTCH1 promoter containing the GRE site. These results demonstrate that NR3C1 directly associate with the NOTCH1 promoter region containing the functional GRE-binding site. The GC-induced downmodulation of Notch1 in KE-37 cells suggests that the GC-induced apoptosis of KE-37 cells might be mediated by the inhibition of a Notch1-mediated anti-apoptotic response. However, the possibility exists that the apoptosis observed in GC-treated KE-37 cells may be mediated only in part by downmodulation of Notch1 expression and alternatively, may be mediated by inhibition of other GCsensitive pathways. To explore this possibility and analyze whether in KE-37 cells GC-mediated apoptosis requires Notch1 downmodulation, we tested whether intracellular Notch1 expression can rescue the GC-induced apoptosis in KE-37 cells. Thus, KE-37 cells were infected with retroviruses containing pMSCVNotch1-IC or control vector pMSCV. Infected cells were then G418 selected and treated with either vehicle or DEX. At 24 h after treatment, apoptosis/viability was evaluated with the use of Annexin-V. The presence of the active form of Notch1 in KE-37 cells increased resistance to GC-induced apoptosis (Figure 2d) , and this was associated with the increased expression of Hes-1 and NR3C1 downmodulation as compared with KE-37 cells infected with the control virus (Figure 2e ). Taken together, these data demonstrate that Notch1-IC expression driven by a heterologous promoter confers DEX resistance to KE-37 cells by promoting glucocorticoid receptor downmodulation, thus inhibiting the DEXmediated apoptotic response. We observed that, although KE-37 cells expressing endogenous Notch1 were sensitive to GC-induced apoptosis (Figure 1) , conversely, Notch1-IC-enforced expression in KE-37 cells had an effect on GC susceptibility. An ensuing question was why does not endogenous NOTCH1 confer GC resistance on KE-37 cells? To address this question we analyzed the level of activated Notch1 in Jurkat, Molt3 and KE-37 cells. We found that both Jurkat and Molt3 cells have functionally active Notch1, as revealed by anti-val1744 Notch1 antibody reactivity, whereas KE-37 cells do not express cleaved Notch1 (Figure 2f ). Consistently with their expression of activated Notch1, Jurkat and Molt3 cells express the Notch1 target gene Hes-1 (Figure1 and Figure 2f ). This indicates that endogenous Notch1 signaling is not active in the KE-37 cells, which fits with the observation that KE-37 cells had a higher level of NR3C1 protein as compared with Jurkat and Molt3 cells.
To inhibit NOTCH-mediated signal transduction, we treated T-ALL cell lines with the GSI-IX (DAPT) at 5 mM, or with dimethyl sulfoxide (control vehicle). We did not observe any effects on proliferation or viability when the treatment was maintained for up to 7 days in any of the cell lines (Figure 2h , only 48 h treatment is shown). Importantly, treatment with DAPT as early as 12 h led to reduced levels of activated Notch1 and Hes-1 in each of the T-ALL cell lines in which the V1744 cleaved protein could be detected, indicating that the compound effectively inhibited NOTCH1 cleavage and activation (Figure 2f , time-point at 24 h is shown). Western blot analysis also demonstrated that the cell lines with activated Notch1 expressed low levels of NR3C1 (Figure 2g ), reflecting the fact that aberrant activation of the NOTCH pathway could be important in glucocorticoid receptor downmodulation. However, after DAPT treatment, both Jurkat and Molt3 cell lines also expressed low levels of NR3C1, implying that glucocorticoid receptor expression is repressed in these cell lines through a mechanism other than NOTCH1/Hes-1 activation. Consistently, GSI treatment did not sensitize Jurkat and Molt3 cells to DEX treatment (Figure 2h ), even though Hes-1 expression was reduced (Figure 2f) . Thus, while confirming that glucocorticoid resistance of T-ALL cells requires an intact Notch signaling, we showed that glucocorticoid treatment reduces Notch1 expression specifically in glucocorticoid-sensitive T-ALL. To conclude, our data indicate that any factors that modulate NR3C1 signaling will also affect Notch1 expression and response. Thus, this mechanism could be exploited to protect cells from an excessive Notch1 response, particularly relevant in those diseases where Notch1 expression is likely to have a key role in pathogenesis.
